Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Long-term, Randomized, Double-blind Extension Study of the Safety, Tolerability, and Efficacy of Aclidinium Bromide at Two Dose Levels When Administered to Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
Brief Summary: The purpose of this extension study is to evaluate the long-term safety, tolerability, and efficacy of inhaled aclidinium bromide at two dose levels in patients with moderate to severe chronic obstructive pulmonary disease (COPD). This study will be 54 weeks in duration; a 52-week double-blind treatment period and 2 week follow-up phone call, following a 12 week lead-in study. All patients will be randomized from the lead-in study at one of two doses of aclidinium.


Options:
A: Arm Label: Aclidinium/Formoterol 400/6 μg; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium Bromide/Formoterol Fumarate | Arm Label: Aclidinium/Formoterol 400/12 μg; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium Bromide/Formoterol Fumarate | Arm Label: Aclidinium monotherapy 400 μg; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium Bromide | Arm Label: Formoterol monotherapy 12 μg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Formoterol Fumarate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aclidinium Bromide/Formoterol Fumarate; Assigned to Arm(s): Aclidinium/Formoterol 400/6 μg | Intervention Type: DRUG; Name: Aclidinium Bromide/Formoterol Fumarate; Assigned to Arm(s): Aclidinium/Formoterol 400/12 μg | Intervention Type: DRUG; Name: Aclidinium Bromide; Assigned to Arm(s): Aclidinium monotherapy 400 μg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Formoterol Fumarate; Assigned to Arm(s): Formoterol monotherapy 12 μg
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium bromide | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium bromide | Intervention Type: DRUG; Name: Aclidinium bromide; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Aclidinium bromide; Assigned to Arm(s): 2
C: Arm Label: Aclidinium bromide 100 μg bid; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium bromide 100 μg bid | Arm Label: Aclidininum bromide 200 μg bid; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium bromide 200 μg bid | Arm Label: Aclidininum bromide 400 μg bid; Type: EXPERIMENTAL; Interventions: Drug: Aclidininum bromide 400 μg bid | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Formoterol 12 μg bid; Type: ACTIVE_COMPARATOR; Interventions: Drug: Formoterol 12 μg bid | Intervention Type: DRUG; Name: Aclidinium bromide 100 μg bid; Assigned to Arm(s): Aclidinium bromide 100 μg bid | Intervention Type: DRUG; Name: Aclidinium bromide 200 μg bid; Assigned to Arm(s): Aclidininum bromide 200 μg bid | Intervention Type: DRUG; Name: Aclidininum bromide 400 μg bid; Assigned to Arm(s): Aclidininum bromide 400 μg bid | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Formoterol 12 μg bid; Assigned to Arm(s): Formoterol 12 μg bid
D: Arm Label: Aclidinium 200 μg once-daily; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium bromide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aclidinium bromide; Assigned to Arm(s): Aclidinium 200 μg once-daily | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B